×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVXL – anavex life sciences corp. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVXL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/15
04:33 am
avxl
Anavex Life Sciences Highlights Oral Alzheimer's Drug Blarcamesine, Precision Strategy at JPM Conference [Yahoo! Finance]
Low
Report
Anavex Life Sciences Highlights Oral Alzheimer's Drug Blarcamesine, Precision Strategy at JPM Conference [Yahoo! Finance]
1/13
07:30 am
avxl
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
Medium
Report
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
1/8
08:13 pm
avxl
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm
Low
Report
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm
1/8
10:00 am
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
1/8
07:30 am
avxl
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Medium
Report
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
1/6
12:40 pm
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL
1/6
09:55 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Medium
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
1/6
07:30 am
avxl
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
Low
Report
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
Date
Time
Symbol
Company Name
Action
%Chg
11/25/2025
07:30 am
avxl
anavex life sciences corp.
BEAT
Report
9.8%
anavex life sciences corp.
8/12/2025
07:30 am
avxl
anavex life sciences corp.
MISS
Report
-0.7%
anavex life sciences corp.
5/13/2025
07:30 am
avxl
anavex life sciences corp.
BEAT
Report
-5.7%
anavex life sciences corp.
2/12/2025
07:30 am
avxl
anavex life sciences corp.
BEAT
Report
3.8%
anavex life sciences corp.
Date
Time
Symbol
Headline
Impact
1/9
05:27 pm
avxl
Form 4 ANAVEX LIFE SCIENCES For: Jan 06 Filed by: MISSLING CHRISTOPHER U
Low
Report
Form 4 ANAVEX LIFE SCIENCES For: Jan 06 Filed by: MISSLING CHRISTOPHER U
1/9
05:26 pm
avxl
Form 4 ANAVEX LIFE SCIENCES For: Jan 06 Filed by: Boenisch Sandra
Low
Report
Form 4 ANAVEX LIFE SCIENCES For: Jan 06 Filed by: Boenisch Sandra
11/25
04:32 pm
avxl
Form 10-K ANAVEX LIFE SCIENCES For: Sep 30
High
Report
Form 10-K ANAVEX LIFE SCIENCES For: Sep 30
11/25
07:31 am
avxl
Form 8-K ANAVEX LIFE SCIENCES For: Nov 25
High
Report
Form 8-K ANAVEX LIFE SCIENCES For: Nov 25
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/4
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Conference
30.6%
9/13 Form S-3/A ANAVEX LIFE SCIENCES 18.1%
3/23 Form DEFA14A ANAVEX LIFE SCIENCES 12.4%
2/14 Form SC 13G/A ANAVEX LIFE SCIENCES Filed by: Park West Asset Management LLC 11.9%
2/6 Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates 9.2%
2/4 Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference 8.8%
2/3 Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome 5.1%
4/8 Form 8-K ANAVEX LIFE SCIENCES For: Apr 07 5.1%
12/5 Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma [Seeking Alpha] 4.9%
6/18 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 4.5%
9/13 Form S-3/A ANAVEX LIFE SCIENCES 18.1%
3/23 Form DEFA14A ANAVEX LIFE SCIENCES 12.4%
2/14 Form SC 13G/A ANAVEX LIFE SCIENCES Filed by: Park West Asset Management LLC 11.9%
2/6 Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates 9.2%
2/4 Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference 8.8%
2/3 Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome 5.1%
4/8 Form 8-K ANAVEX LIFE SCIENCES For: Apr 07 5.1%
12/5 Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma [Seeking Alpha] 4.9%
6/18 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 4.5%
TOP News Decliners
4/1
Anavex Life Sciences Corp (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
-10.5%
9/27 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study -9.7%
7/3 Form S-3 ANAVEX LIFE SCIENCES -8.9%
7/29 Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome -8.7%
2/26 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. -8.0%
6/13 Anavex Life Sciences Corp (NASDAQ: AVXL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
2/24 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) -7.3%
2/6 Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call Transcript [Seeking Alpha] -7.2%
11/6 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome -5.9%
3/31 Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 -4.8%
9/27 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study -9.7%
7/3 Form S-3 ANAVEX LIFE SCIENCES -8.9%
7/29 Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome -8.7%
2/26 Anavex Life Sciences Corp (NASDAQ: AVXL) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. -8.0%
6/13 Anavex Life Sciences Corp (NASDAQ: AVXL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
2/24 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) -7.3%
2/6 Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call Transcript [Seeking Alpha] -7.2%
11/6 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome -5.9%
3/31 Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: